Mesoblast Limited (OTCMKTS:MEOBF – Get Free Report) saw a significant decline in short interest during the month of March. As of March 31st, there was short interest totaling 34,393,117 shares, a decline of 14.2% from the March 15th total of 40,078,152 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is presently 343,931.2 days.
Mesoblast Stock Performance
Shares of Mesoblast stock opened at $1.60 on Friday. Mesoblast has a 1 year low of $0.96 and a 1 year high of $2.59. The company’s fifty day simple moving average is $1.58 and its 200-day simple moving average is $1.59.
About Mesoblast
Mesoblast Limited (OTCMKTS:MEOBF) is a global leader in regenerative medicine focused on the development and commercialization of innovative allogeneic cell therapies. The company’s proprietary platform harnesses mesenchymal lineage adult stem cells to address a range of inflammatory and immunological conditions. Mesoblast’s pipeline includes multiple late-stage and marketed products that target serious diseases with high unmet medical needs.
The company’s lead product, remestemcel-L (Ryvicor/Ryoncil), is under development for the treatment of steroid-refractory acute graft versus host disease in pediatric patients and has received conditional approval for certain indications in Japan.
Featured Stories
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.
